1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Insys seeks fast cash, Nasdaq listing with IPO

 
• By Mandy Jackson

Insys Therapeutics intends to raise up to $82.8 million in an initial public offering of 4 million shares priced at $16 to $18 each plus the sale of additional shares to meet overallotments; the IPO would move the Phoenix, Arizona-based company to the Nasdaq from the Over-the-Counter market to generate much needed cash from a larger pool of investors.

Insys Therapeutics intends to raise up to $82.8 million in an initial public offering of 4 million shares priced at $16 to $18 each plus the sale of additional shares to meet overallotments; the IPO would move the Phoenix, Arizona-based company to the Nasdaq from the Over-the-Counter market to generate much needed cash from a larger pool of investors.

Insys, which focuses on cancer supportive care and other products, closed at $11.99 per share on 19 April on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Therapeutic Category

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.